Hepatocellular Carcinoma
Hepatocellular carcinoma develops predominantly on cirrhotic liver backgrounds and requires simultaneous management of tumor burden and underlying liver function. BCLC staging, Child-Pugh score, and AFP trajectory guide decisions across surgery, ablation, TACE, TARE, and systemic therapy. CancerFax helps patients access atezolizumab-bevacizumab combinations, TARE programs, and specialist hepato-oncology centers internationally including in China.
- BCLC staging, AFP & liver function assessment
- TACE, TARE, IO combinations & targeted therapy
- China liver cancer center & advanced trial access
- Median Age at Diagnosis
- 64 years
- 5th Most Common Cancer
- Worldwide
- Male to Female Ratio
- 3:1
- 5-Year Survival
- 18% overall
- Occurs in Cirrhosis
- 80-90%
What is Hepatocellular Carcinoma
Types and Subtypes
Hepatocellular carcinoma is classified by disease stage, which determines treatment approach and prognosis. The Barcelona Clinic Liver Cancer (BCLC) staging system is most commonly used and incorporates tumor characteristics, liver function, and performance status.
Symptoms and Signs
Hepatocellular carcinoma often develops silently in patients with cirrhosis or chronic hepatitis. Early-stage HCC may be asymptomatic and detected only through surveillance imaging. As disease progresses, patients may develop symptoms related to the tumor itself or worsening liver function.
Causes and Risk Factors
Hepatocellular carcinoma develops through a multistep process involving chronic inflammation, fibrosis, cirrhosis, and accumulation of genetic alterations. The most significant risk factors are chronic viral hepatitis and cirrhosis, which account for the majority of HCC cases globally.
Diagnosis and Investigations
Diagnosis of hepatocellular carcinoma is based on imaging characteristics in the setting of cirrhosis or chronic liver disease, supplemented by biomarkers and tissue biopsy when needed. Early detection through surveillance in at-risk patients improves outcomes. Accurate diagnosis and staging are essential for treatment planning.
Disease Staging and Risk Stratification
Hepatocellular carcinoma is staged using the Barcelona Clinic Liver Cancer (BCLC) staging system, which incorporates tumor burden, liver function (Child-Pugh class), and performance status. Stage at diagnosis is the most important prognostic factor and guides treatment selection.
Standard Treatment Options
Management of HCC is multimodal and based on the stage of the disease, degree of liver dysfunction, and patient’s performance status. Early-stage disease presents the highest chances of cure, while late-stage cases need systemic treatment. Liver transplantation presents the best chance of cure in early-stage HCC patients who are cirrhotic.
Advanced & Emerging Therapies
Significant advances in HCC treatment have occurred in recent years, particularly in immunotherapy and combination approaches. These emerging therapies are improving outcomes, especially for advanced disease, and are expanding treatment options across all disease stages.
Immunotherapy
Checkpoint Inhibitors and Combinations
Atezolizumab + bevacizumab (anti-PD-L1 + anti-VEGF) shows improved outcomes vs. sorafenib. Nivolumab + ipilimumab (anti-PD-1 + anti-CTLA-4) approved for advanced HCC. Pembrolizumab monotherapy also approved. These represent major advances in systemic therapy.
Targeted Therapy
Multi-Kinase Inhibitors
Lenvatinib (multikinase inhibitor) approved for first-line advanced HCC. Regorafenib and cabozantinib approved for second-line. These agents target multiple pathways driving HCC growth.
Combination Therapy
Targeted + Immunotherapy Combinations
Emerging data support combinations of targeted therapy with immunotherapy. Bevacizumab + immunotherapy combinations showing promise. Ongoing trials investigating optimal combinations.
Surgical Innovation
Liver Transplantation
Excellent outcomes for early-stage HCC in cirrhotic patients. Transplant offers both tumor cure and cirrhosis treatment. Milan criteria traditionally used for selection. Expanded criteria being evaluated.
Locoregional Therapy
Radioembolization (TARE)
Yttrium-90 radioembolization delivers radiation directly to tumor. May be combined with systemic therapy. Emerging data support improved outcomes.
Radiation Therapy
Stereotactic Body Radiation Therapy (SBRT)
Advanced radiation technique for small HCC tumors. May be used for tumors not amenable to surgery or ablation. Emerging role in multimodal treatment.
Systemic Therapy
Emerging Agents and Combinations
Novel agents targeting HCC pathways under investigation. Combination approaches with immunotherapy and targeted therapy being studied. Personalized therapy based on tumor molecular profiling emerging.
Biomarkers & Molecular Features
Molecular profiling of hepatocellular carcinoma is increasingly important for understanding tumor biology, predicting treatment response, and guiding personalized therapy. Multiple biomarkers have prognostic and predictive significance.
When to Seek a Second Opinion
Expert review is particularly valuable in hepatocellular carcinoma given the complexity of treatment options and the importance of accurate staging and liver function assessment. Second opinion is recommended at multiple points in the treatment course.
Clinical Trials & Research
Prognosis & Outcome Factors
Prognosis for hepatocellular carcinoma varies dramatically based on disease stage, liver function, and treatment response. Early-stage disease detected through surveillance offers the best outcomes, while advanced disease has more limited prognosis but improving with newer therapies.
Supportive Care & Living With Hepatocellular Carcinoma
Supportive care is an essential component of hepatocellular carcinoma management, addressing both the physical and emotional impacts of the disease and its treatment on the patient and family.
How CancerFax Helps You Explore Treatment Options
CancerFax assists patients and families with hepatocellular carcinoma by coordinating expert review of diagnostic imaging, biopsy results, liver function tests, AFP levels, and hepatitis serology to confirm accurate diagnosis and staging. We connect patients with specialist hepatologists, surgical oncologists, and transplant surgeons experienced in comprehensive HCC management. We facilitate access to surgery, liver transplantation, ablation, embolization, targeted therapy, immunotherapy, and clinical trial opportunities at major hepatology and oncology centers globally, including specialized institutions in China.
Get a free case reviewFrequently Asked Questions
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It accounts for >90% of primary liver tumors and is the fifth most common cancer worldwide. HCC usually develops in patients with cirrhosis or chronic liver disease from hepatitis B, hepatitis C, or other causes.
HCC is caused by chronic liver inflammation and cirrhosis. Major causes include chronic hepatitis B (56% of cases), hepatitis C (20%), alcoholic liver disease (30% in US), and non-alcoholic fatty liver disease (increasingly common). Other factors include aflatoxin exposure and metabolic disorders. Cirrhosis is present in 80-90% of HCC cases.
Early-stage HCC is often asymptomatic and detected through surveillance. Symptoms develop as disease progresses and include abdominal pain, weight loss, loss of appetite, nausea, vomiting, jaundice, itching, abdominal swelling (ascites), fatigue, dark urine, and easy bruising. Symptoms may be from the tumor or from worsening liver function.
Diagnosis is based on imaging (CT or MRI) showing arterial enhancement with washout in the setting of cirrhosis or chronic liver disease. AFP level may be elevated. Biopsy confirms diagnosis when imaging is inconclusive. Staging includes chest imaging to detect metastases and assessment of liver function.
The Barcelona Clinic Liver Cancer (BCLC) staging system has five stages: Stage 0 (very early), Stage A (early), Stage B (intermediate), Stage C (advanced), and Stage D (end-stage). Stage is determined by tumor size/number, vascular invasion, extrahepatic spread, liver function, and performance status. Stage guides treatment selection.
Treatment depends on stage and liver function. Early-stage HCC (Stage 0-A) can be cured with surgery (hepatectomy), liver transplantation, or ablation. Intermediate-stage (Stage B) is treated with chemoembolization or embolization. Advanced-stage (Stage C) requires systemic therapy with immunotherapy or targeted therapy. End-stage (Stage D) focuses on palliative care.
Liver transplantation offers excellent outcomes for early-stage HCC in cirrhotic patients, treating both the tumor and cirrhosis. Milan criteria traditionally used for selection (single tumor <5 cm or up to 3 tumors <3 cm each). Expanded criteria being evaluated. Transplant offers best long-term survival for eligible patients.
5-year overall survival is 18% but varies by stage: Stage 0 ~70%, Stage A 50-60%, Stage B 30-40%, Stage C 10-15%, Stage D <5%. Early detection through surveillance and appropriate treatment offer best outcomes. Newer immunotherapy and targeted therapy have improved outcomes for advanced disease.
Yes. CancerFax helps patients and families with hepatocellular carcinoma by coordinating expert review of imaging, biopsy, and laboratory results to confirm diagnosis and staging. We connect patients with specialist hepatologists, surgical oncologists, and transplant surgeons. We facilitate access to all treatment modalities and provide guidance on transplant evaluation and international treatment coordination.